Submit Manuscript  

Article Details


Pentraxin Level is the Key to Determine Primary Percutaneous Coronary Intervention (PCI) or Fibrinolysis

[ Vol. 19 , Issue. 2 ]

Author(s):

Habib Haybar, Saeed Alipour Parsa, Isa Khaheshi and Zeinab Deris Zayeri*   Pages 160 - 168 ( 9 )

Abstract:


Aims: To examine if pentraxin can help identify patients benefitting most from primary Percutaneous Coronary Intervention (PCI) vs. fibrinolysis.

Methods: Patients with acute ST-Elevation Myocardial Infarction (STEMI) were consecutively recruited from a community center without PCI and a tertiary center with PCI facilities. Left ventricular ejection fraction (LVEF) was determined echocardiographically at baseline and 5 days after the index admission; the difference between two measurements was considered as the magnitude of improvement. We used regression models to test the hypothesis that the magnitude of the advantage of PCI over fibrinolysis in preserving LVEF 5 days after STEMI is modified by pentraxin 3 (PTX3).

Results: The functional advantage (LVEF) of the PCI over fibrinolysis has been determined by PTX3. LVEF was attenuated and even reversed as PTX3 level increased. The primary PCI of the participants with less than 7 ng.ml-1 PTX3 level, achieved a clinically significant increase in the LVEF as compared to fibrinolysis. At lower levels of PTX3, PCI shows a conspicuous advantage over fibrinolysis in terms of the probability of developing an LVEF <40%.

Conclusion: We demonstrated not only the functional advantage of PCI over fibrinolysis performed within the recommended time frames but also the relative advantage of its relevance to the baseline PTX3 levels. PTX3 can play a role in determining the choice of best therapy. More than 75% of patients with STEMI who have PTX3 levels ≤7 ng.ml-1 imply the need of PCI.

Keywords:

Fibrinolysis, pentraxin, ejection fraction, percutaneous coronary intervention, st-elevation myocardial infarction, cholesterol.

Affiliation:

Atherosclerosis research center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz

Graphical Abstract:



Read Full-Text article